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direct evidence has not been proven clinically. MS epidemics 
have been shown to be primarily associated with exposure to 
virus infections, and the roles of human herpes virus (HHV)-
6 and Epstein-Barr virus (EBV) are being actively investi-
gated (12–14). It has been suggested that microbial infections 
can lead to bystander activation (15, 16) or de novo genera-
tion of autoreactive cells as a result of the release of cryptic 
antigenic determinants and/or epitope spreading in infected 
individuals (17). Alternatively, microbial products bearing 
the sequences identical to those in self-antigens can lead to 
the generation of cross-reactive cells, a phenomenon known 
as molecular or antigenic mimicry (18).
In our efforts to identify the disease-inducing microbial 
mimics for PLP 139–151, we recently identified a novel 
epitope from Acanthamoeba castellanii (ACA), 83–95, which 
induces EAE in SJL mice by generating cross-reactive cells 
for PLP 139–151 (19). We also demonstrated that the patho-
genicity of ACA 83–95-induced PLP-specific cells differs by 
gender but is independent of cytokine responses, in that the 
cross-reactive cells generated in males fail to induce the dis-
ease in females but not vice versa, suggesting modulation 
of cross-reactive immune responses by sex hormones (20). 
Regardless of gender, however, the TCR vβ usage of cross-
reactive T cells induced with ACA 83–95 differs from that 
of cells induced with PLP 139–151. By using PLP 139–151/
IAs tetramers, we showed that the TCR vβ2-expressing PLP 
Introduction
Multiple sclerosis (MS) is believed to be an autoimmune 
disease of the central nervous system (CNS), and autoreac-
tive T cells and B cells have been implicated in the disease 
pathogenesis (1, 2). Three candidate autoantigens—myelin 
proteolipid protein (PLP), myelin basic protein (MBP) and 
myelin oligodendrocyte glycoprotein (MOG)—have been 
identified in MS pathogenesis, and MS patients show vary-
ing degrees of T cell and antibody responses to all three (1, 
3–5). The importance of these antigens has been well studied 
in the rodent models of experimental autoimmune enceph-
alomyelitis (EAE) by inducing the disease with the immu-
nodominant epitopes of myelin antigens, the phenotypes of 
which vary with different genetic backgrounds. For example, 
MBP Ac 1–11 induces the monophasic form of EAE in B10.PL 
or PL/J mice (IAu); MOG 35–55 induces the chronic progres-
sive form in C57BL/6 mice (IAb) and PLP 139–151 induces 
relapsing remitting paralysis, whereas MBP 89–101 induces 
the chronic or relapsing form of EAE in SJL mice (IAs) (6–11). 
Likewise, the MBP fragment encompassing 89–101/87–99, 
restricted by the MHC class II allele RT1D, induces the mono-
phasic form of EAE in Lewis rats (11). These phenotypes re-
semble some of the clinical features of MS, thus making the 
observations seen in rodents relevant to humans.
Exposure to environmental microbes such as viruses and 
bacteria has long been suspected in the initiation of MS, but 
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Abstract
We had previously reported that Acanthamoeba castellanii (ACA) contains a mimicry epitope for proteolipid protein 139–151 
capable of inducing central nervous system (CNS) autoimmunity in SJL/J mice. We now present evidence that ACA also con-
tains a mimicry epitope for myelin basic protein (MBP) 89–101, a derivative from amoebic nicotinamide adenine dinucleotide 
dehydrogenase subunit 2 (NAD). The epitope, NAD 108–120, contains a discontinuous stretch of six amino acids in the core 
region (VVFFKNIILIGFL) sharing 46% identity with MBP 89–101 (VHFFKNIVTPRTP; identical residues are underlined). SJL 
mice immunized with NAD 108–120 develop encephalomyelitis similar to the disease induced by the cognate peptide. We 
demonstrate that NAD 108–120 induces T cells that cross-react with MBP 89–101; the antigen-sensitized T cells, which produce 
predominantly T helper (Th) 1 and Th17 cytokines, transfer disease in naive SJL recipients reminiscent of the disease induced 
with MBP 89–101. This is the first report to demonstrate that a solitary microbe can induce CNS autoimmunity by generating 
cross-reactive T cells for multiple myelin antigens.
Keywords: Experimental autoimmune encephalomyelitis, Multiple sclerosis, Molecular mimicry, Myelin basic protein, Acan-
thamoeba castellanii
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PyMOL software (http://www.pymol.org).
Peptide synthesis and immunization procedures
NAD 108–120, MBP 89–101 and Theiler’s murine encepha-
lomyelitis virus (TMEV) 70–86 (WTTSQEAFSHIRIPLP) were 
synthesized on 9-fluorenylmethyloxycarbonyl chemistry 
(Neopeptide, Cambridge, Massachusetts, U.S.A.). All pep-
tides were HPLC-purified (>90%) and confirmed by mass 
spectroscopy and then dissolved in sterile 1× PBS (MBP 89–
101) or 1× PBS/dimethyl sulfoxide (DMSO) (NAD 108–120). 
For disease induction, peptides dissolved in 1× PBS were 
emulsified in complete Freund’s adjuvant (CFA) supple-
mented with Mycobacterium tuberculosis (MTB) H37RA ex-
tract (Difco Laboratories, Detroit, Michigan, U.S.A.) to a final 
concentration of 5 mg ml1, and the peptide emulsions were 
administered twice in the sternal and inguinal regions with 
an interval of 7 days (6). In addition, pertussis toxin (PT; List 
Biological Laboratories, Campbell, California, U.S.A.) was 
administered (400 ng per mouse) intraperitoneally on day 0 
and day 2 post-immunization after the first immunization (6, 
8, 22) only. To measure recall responses, MBP 89–101 and 
NAD 108–120 dissolved respectively, in 1× PBS and DMSO 
were emulsified in CFA containing no additional MTB ex-
tract and administered as above.
Clinical scoring and histopathology
After EAE induction, the mice were monitored for clinical 
signs of disease and scored as described previously (8, 22): 
0, healthy; 1, decreased tail and body tone; 2, a clumsy but 
otherwise normal gait; 3, definite weakness of one or more 
limbs; 4, a paraplegic or monoplegic state and 5, a premor-
bid state. Animals were euthanized during recovery or upon 
termination on day 30 post-immunization. Brain and spinal 
cords were collected in 10% phosphate-buffered formalin and 
analyzed for histological evidence of inflammatory changes 
(19, 23). After fixation, two brain sections were made; one in-
cluded cerebrum and hippocampus, and the second included 
cerebellum and brainstem. In the spinal cord, three sections 
were made from each segment (cervical, thoracic, lumbar 
and sacral). All the tissues were stained by hematoxylin and 
eosin staining. Tissues were blinded to treatment, lesion type 
was characterized and severity was scored. Severity scores 
were obtained by counting inflammatory foci in both menin-
ges and parenchyma for all sites. Inflammation was primar-
ily classified as lymphocytic, suppurative or mixed (19, 20). 
For statistical analysis, counts were added across all sections 
of brain and spinal cord for each mouse.
Adoptive transfer EAE
Groups of five mice were immunized twice with MBP 89–
101 or NAD 108–120 (200 μg per mouse) with a 7-day interval 
between immunizations; 7 days after the second immuniza-
tion, the animals were killed, and LNC were prepared from 
the draining lymph nodes (LNs). LNC were stimulated with 
Concanavalin-A (Con-A) at a concentration of 1 μg ml-1 for 
2 days as described previously (6, 24). Viable lymphoblasts 
were harvested by Ficoll-Hypaque density-gradient centrifu-
gation, and 60 × 106 cells were administered intraperitoneally 
into groups of five naive SJL mice. Additionally, each animal 
received PT (400 ng) on days 0 and 2 post-transfer, and the 
animals were monitored for clinical signs of EAE and scored 
139–151-specific CD4 cells are skewed in mice immunized 
with ACA 83–95, indicating that exposure to microbial mim-
ics can lead to the selective expansion of T cell clones that 
differ from those generated by cognate epitopes (20). In this 
report, we present evidence that ACA also contains a mim-
icry epitope for MBP 89–101 and that the epitope spanning 
108–120 amino acids represents the nicotinamide adenine di-
nucleotide dehydrogenase subunit 2 (NAD) of Acanthamoeba. 
We demonstrate that NAD 108–120 induces clinical and his-
tological features of EAE similar to those induced by the cog-
nate peptide in SJL mice by generating cross-reactive T cells 
for MBP 89–101 and pro-inflammatory cytokines that favor 
CNS autoimmunity.
Methods
Mice
Four- to -six-week-old female SJL/J (H-2s) mice were ob-
tained from the Jackson Laboratory (Bar Harbor, Maine, 
U.S.A.). The mice were maintained in accordance with the 
animal protocol guidelines of the University of Nebraska-
Lincoln, Lincoln, Nebraska, U.S.A.
Identification of NAD 108–120
Using the LALIGN server (http://www.ch.embnet.org/
software/LALIGN_form.html), we searched for identical 
sequences of MBP 89–101 (VHFFKNIVTPRTP) by compar-
ing ~200 known protein sequences of ACA retrieved from 
National Center for Biotechnology Information protein data-
base (http://www.ncbi.nlm.nih.gov/). This search resulted 
in the identification of one epitope spanning the amino ac-
ids 108–120 within the NAD of ACA (VVFFKNIILIGFL). All 
the data were generated using NAD 108–120, except for the 
homology model for which we used the sequence of NAD 
104–118 (NDAAVVFFKNIILIG) by including four additional 
residues at the N-terminal end and excluding two residues at 
the C-terminal end from NAD 108–120. The sequence length 
of NAD 104–118 is consistent with that of MBP 85–99 used in 
the structural study (21).
Derivation of NAD 104–118/HLA-DR2 homology model
To determine differences between MBP 85–99 and NAD 
104–118 with respect to their MHC-contact residues within 
the binding pockets of HLA-DR2 molecule, we used the crys-
tal structure of HLA-DR2 (DRA, DRB1*1501) complexed with 
human MBP 85–98 or MBP 86–99 as a reference model (21). 
The coordinates of these structures (1BX2) were obtained from 
the Research Collaboratory for Structural Bioinformatics Pro-
tein Data Bank (http://www.rcsb.org) and used with the kind 
permission from Dr. Kai Wucherpfennig, Harvard University, 
Boston, Massachusetts, U.S.A. The MBP 85–99 reference model 
was generated by averaging the monomers from the original 
crystal structure complexed with MBP 85–98 for one mono-
mer and with MBP 86–99 for the other. The averaged structure 
was three dimensional-protonated and energy-minimized 
using MMFF94x restraints within MOE software to yield an 
optimized MBP 85–99/HLA-DR2 structure (Chemical Com-
puting group, Montreal, Canada). The optimized MBP 85–99/
HLADR2 model was then used as a template to generate a ho-
mology model for HLA-DR2 molecule complexed with NAD 
104–118, and the structure was optimized using MOE as de-
scribed above. The figures of the model were generated using 
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Analysis of TCR vβ usage
LNC harvested from the mice immunized with MBP 89–
101 or NAD 108–120 were stimulated with the correspond-
ing peptides for 2 days (20 μg ml-1), and the cultures were 
maintained in IL-2 medium. Cells were harvested on day 4 
post-stimulation with peptides and stained with a panel of 
anti-mouse TCR vβ antibodies: vβ 2, 3, 4, 5.1, 5.2, 6, 7, 8.1, 
8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a (BD Pharmingen), anti-
CD4 and 7-AAD. After acquiring the cells by FC, percentages 
of TCR vβ+ cells were enumerated in the live (7-AAD-) CD4 
population (20).
Statistics
Comparisons of histological disease between groups for in-
flammatory lesions in the brain and spinal cords were ana-
lyzed by two-sided Wilcoxon rank sum test (Mann–Whitney 
U-test). Differences in the cumulative neurological scores 
of animals with EAE and cytokine secretion with respect to 
T helper (Th)1, Th 2 and Th17 subsets between groups were 
compared by student’s t-test. P < 0.05 values were consid-
ered significant.
Results
NAD 108–120 has the structural characteristics of binding to 
HLA-DR2 molecules
By sequence comparisons, we identified NAD 108–120 as 
the mimicry epitope for MBP 89–101 showing a similar-
ity of 46.2% and containing a discontinuous stretch of six 
amino acids (VVFFKNI) in the core region [Figure 1A(i)]. 
This region within human MBP 85–99 represents an epitope 
center for recognition by both TCR and auto-antibodies (5). 
Further more, by crystal study of HLA-DR2 (DRA*0101, 
DRB1*1501) complexed with human MBP 85–99, the critical 
MHC-contact residues in MBP 85–99 have been well char-
acterized (21). These include Val89 and Phe92 as primary 
anchor residues, the latter being the most critical and they 
bind to P1 and P4 pockets, respectively, in the HLA-DR2 
molecule. Three other amino acids, Asn94, Ile95 and Thr97, 
were identified as the secondary MHC-contact residues 
binding to the P6, P7 and P9 pockets, respectively (21). 
Both MBP 85–99 and NAD 104–118 have identical residues 
in all the above positions, except that Thr97 in MBP 85–99 
is substituted with Leu116 in NAD 104–118 [Figure 1A(ii)]. 
To understand the structural characteristics of MHC bind-
ing, we derived a homology model for NAD 104–118/
HLA-DR2, which agreed well with the reference structure 
(Figure 1B), with an overall root mean square deviation of 
0.70 Å for all atoms (Figure 1C). Expectedly, the side chains 
of the conserved Phe 92/111 in MBP 85–99/NAD 104–118 
superposed well, and the distance between their alpha 
carbon atoms was 1.3 Å (Figure 1D). Likewise, while the 
orientation of Asn (94/113) in MBP 85–99/NAD 104–118 
was comparable (1.4 Å), the side chains of Val (89/108) 
and Ile (95/114) were shifted, and their C-alpha positions 
were 3.2 and 1.5 Å, respectively  (Figure 1D). The position 
shifts were consistent with energy minimization, and all 
the identical residues retained their ability to bind in ap-
propriate pockets. The homology model also provided ad-
ditional information on TCR-contact residues. Previously, 
it was shown that Phe91 and Lys93 in MBP 85–99 are the 
major TCR-contact residues, whereas His90 is less criti-
as above (8, 22, 6). The experiments were terminated on day 
21 postinoculation, and the CNS tissues were harvested for 
histology (19, 20).
Proliferation assay
Groups of mice were immunized with MBP 89–101 or NAD 
108–120, and after 10 days, the animals were killed and the 
draining LN collected to prepare single-cell suspensions. 
LNC were stimulated with MBP 89–101, NAD 108–120 and 
TMEV 70–86 (0–100 lgml1) at a cell density of 5 × 106 cells/
ml for 2 days in RPMI medium supplemented with 10% fetal 
bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine, 
1× each of nonessential amino acids and vitamin mixture 
and 100 U/ml penicillin–streptomycin (Lonza, Walkersville, 
Maryland, U.S.A.). Cultures were then pulsed with 1 μCi of 
tritiated 3[H]thymidine per well; 16 h later, the proliferative 
responses were measured as counts per minute (c.p.m.) using 
a Wallac liquid scintillation counter (Perkin Elmer, Waltham, 
Massachusetts, U.S.A.) hereafter called growth medium. We 
further verified these responses by second-round of re-stim-
ulation with each peptide. LNC obtained from immunized 
mice were first stimulated with MBP 89–101 or NAD 108–
120 (20 μg ml-1) for 2 days and the cells were maintained in 
growth medium containing IL-2. Viable cells were harvested 
on day 4 post-stimulation; rested for ~10 to 14 days and the 
proliferative responses were measured after re-stimulating 
the cells with the indicated peptides as above.
Intracellular cytokine staining
Mice were immunized with MBP 89-101 or NAD 108–120 
and 10 days later, the animals were killed and LN were har-
vested to prepare LNC. Cells were stimulated with the cor-
responding peptides for 2 days (20 μg ml-1) and the cultures 
were maintained in IL-2 medium. Viable lymphoblasts were 
harvested on day 4 and stimulated for 4.5 h with phorbol 
12-myristate 13-acetate (PMA) (20 ng ml-1) and ionomycin 
(300 ng ml-1) (Sigma–Aldrich, St Louis, Missouri, U.S.A.) in 
the presence of 2 mM monensin (GolgiStop; BD Pharmingen, 
San Diego, California, U.S.A.). After staining with anti-CD4 
and 7-aminoactinomycin D (7-AAD; Invitrogen, Eugene, Or-
egon, U.S.A.), cells were fixed, permeabilized and stained 
with cytokine antibodies or isotype controls (eBioscience, 
San Diego, California, U.S.A.; 19, 20). Cells were acquired 
by flow cytometry (FC, FACS Scan; BD Pharmingen), and 
the frequencies of cytokine-secreting cells were analyzed in 
the live (7-AAD) CD4+ subset using Flow Jo software (Tree 
star, Ashland, Oregon, U.S.A.; 19). The clones of cytokine 
antibodies used were: IL-2 (JES6-5H4), IL-4 (11B11), IL-10 
(JES5-16E3), IFN-γ (XMG1.2), IL-17A (eBio 17B7), IL-17F 
(eBio 18F10), granulocyte macrophage-colony stimulating 
factor (GM-CSF) (MP122E9) (all from eBioscience) and IL-22 
(140301) (R&D Systems, Minneapolis, Minnesota, U.S.A.).
Cytokine ELISA
Supernatants harvested from the above cultures on day 2 
were analyzed for cytokines by ELISA (19). The clones of the 
capture and detection antibody pairs used were: IL-2 (JES6-
1A12/JES6-5H4), IL-4 (11B11/BVD6-24G2), IL-10 (JES5-
16E3/JES5-2A5), IL-17A (eBio17CK15A5/eBio17B7), IFN-γ 
(AN-18/R4-6A2), IL-22 (1H8-PWSR/IL-22-JOP) and GM-
CSF (MP1-22E9/MP1-31G6) (eBioscience).
732     Massilamany, Asojo, Gangaplara, Steffen & Reddy in International Immunology (2011) 23(12)
NAD 108–120 induces EAE similar to MBP 89–101
To determine the disease-inducing ability of NAD 108–120, 
we used active immunization and adoptive transfer EAE 
protocols. We immunized groups of mice and followed the 
disease course for 30 days. The CNS tissues were collected 
for histology during remission or upon termination of experi-
ments. We noted that NAD 108–120 induced the disease dose 
dependently ,in that a dose of 50 μg per mouse did not induce 
the disease, whereas the disease severity was moderate in 
animals that received 100 μg (Figure 2A). In contrast, a dose 
of 200 μg NAD 108–120 resulted in EAE severity comparable 
to that induced by MBP 89–101, with a similar mean day of 
onset (12.00 ± 1.32 versus 12.10 ± 0.94) and mean maximum
cal for TCR binding (5). The structure of the MBP 85–99/
HLA-DR2 complex also revealed that these residues were 
exposed, allowing them to be easily accessible to TCR (21). 
Similar to MBP 85–99, NAD 104–118 also has the two major 
TCR-contact residues, Phe110 and Lys112, whereas His90 is 
substituted with Val109 [Figure 1A (ii)]. Among these two 
common residues, the homology model shows that the side 
chains of Phe91/110 superpose almost identically, whereas 
Lys (93/112) is more flexible (Figure 1D). Taken together, 
the homology model suggests that the most critical residue, 
Phe at positions 111 and 110 in NAD 104–118, is expected to 
interact with the P4 pocket of the HLA-DR2 molecule and 
TCR, respectively.
Figure 1. Derivation of homology model for NAD 104–118/HLA-DR2 complex. (A) Comparison of peptide sequences. Amino acid sequences 
were compared with respect to NAD 108–120 versus mouse MBP 89–101 (i) and NAD 104–118 versus human MBP 85–99 (ii). Identical sequences 
are underlined. Top arrows, TCR-contact residues; bottom arrows, MHC-anchor residues. Solid arrows, major contacts; dotted arrows, minor 
contacts. (B) MBP 85–99/HLA-DR2 reference model. The MBP 85–99/HLA-DR2 (DRA, DRB1*1501) reference model was generated by averag-
ing the monomers from the original crystal structure complexed with MBP 85–98 or MBP 86–99 as described in the Methods, and the figure was 
generated in PyMOL software. (C) NAD 104–118/HLA-DR2 homology model. Using MBP 85–99/HLA-DR2 reference model as a template, 
homology model for NAD 104–118 complexed with HLA-DR2 was generated as above. (D) Superposition of MBP 85–99 and NAD 104–118. 
The NAD 104–118/HLA-DR2 complex was superposed over MBP 85–99/HLA-DR2 reference model and the figure was generated in PyMOL 
software. Solid circles, MHC-binding residues correspond to the indicated pockets (P1, P4, P6, P7 and P9) within HLA-DR2 molecule; dotted 
circles, TCR-binding residues.
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however, tended to be lower in mice that received cells from 
NAD 108–120 than those that received MBP 89–101 sensi-
tized cells as evaluated based on cumulative scores (12.60 ± 
1.69 versus 16.60 ± 1.81) [Figure 2C(ii)] and the inflammatory 
foci in CNS tissues [Table 1(ii); Figure 3B]. Taken together, 
the data suggest that NAD 108–120 is an encephalitogenic 
mimicry epitope of MBP 89–101 and disease induction re-
quires the mediation of antigen-sensitized T cells.
MBP 89–101 and NAD 108–120 induce cross-reactive T-cell re-
sponses
Induction of EAE with MBP 89–101 in SJL mice is typi-
cally mediated by CD4 cells (8, 22, 26). The fact that CNS 
inflammation induced by NAD 108–120 was similar to that 
induced by MBP 89–101 suggests that the mimicry epitope 
can induce the generation of cross-reactive T cells for MBP 
89–101. To examine this possibility, we stimulated LNC 
from mice immunized with NAD 108–120 or MBP 89–101 
with the corresponding peptides dissolved in 1× PBS, and 
their recall responses were measured based on 3[H]thymi-
dine incorporation. Expectedly, both MBP 89–101 and NAD 
108–120 induced the dose-dependent proliferative responses 
to the respective peptides, but a fraction of these cells also re-
sponded to unimmunizing peptides (Figure 4). For example, 
LNC from MBP 89–101 immunized mice responded to MBP 
peptide, and approximately one-third of the MBP-reactive T 
cells also showed response to NAD 108–120 [Figure 4A (i)]. 
Similar patterns were observed when NAD 108–120 sensi-
tized LNC were examined for their reactivity to NAD and 
MBP peptides although the reactivity for the latter was rela-
tively low [Figure 4A(ii)]. The responses were antigen spe-
cific since LNC from mice immunized with either MBP 89–
101 or NAD 108–120 did not respond to the control peptide 
(TMEV 70–86). We verified these data by second-round of re-
stimulation with MBP 89–101 or NAD 108–120. Expectedly, 
LNC cultures prepared from MBP 89–101 immunized mice 
responded dose dependently to both MBP 89–101 (7.9-fold) 
and NAD 108–120 [4.9-fold; Figure 4B(i)]. Similar patterns 
were noted when the cultures obtained from NAD 108–120 
immunized mice were re-stimulated with NAD 108–120 (2.9-
fold) and MBP 89–101 [2.8-fold; Figure 4B(ii)]. The data dem-
onstrate that MBP 89–101 and NAD 108–120 induce antigen-
specific cross-reactive T-cell responses.
LNC sensitized with MBP 89–101 or NAD 108–120 produce cy-
tokines that favor CNS autoimmunity
The hallmark of encephalitogenic T cells is their ability to 
secrete Th 1 and Th17 cytokines; in addition, mice deficient in 
GM-CSF show resistance to the development of EAE (27–29). 
We examined Th1 (IL-2 and IFN-γ), Th2 (IL-4 and IL-10), 
Th17 (IL-17A, IL-17F and IL-22) cytokines and GM-CSF in 
LNC obtained from mice immunized with MBP 89–101 or 
NAD 108–120 by both intracellular cytokine detection and 
cytokine ELISA. Figure 5(A) shows that the cells capable of 
secreting all the cytokines tested except IL-4 were present in 
the cultures stimulated with MBP 89–101 or NAD 108–120. 
Their proportions were dominated by both Th1 (12.25 ± 2.14 
versus 11.18 ± 2.65) and Th17 (9.05 ± 1.32 versus 6.13 ± 1.23) 
cytokine-secreting cells (Figure 5A and B). Within the Th17 
subset, however, frequencies of IL-22secreting cells were 
higher than IL-17F and IL-17A or combination of the two 
score (1.90 ± 0.23 versus 2.00 ± 0.15) [Table 1(i)], including the 
cumulative scores (16.00 ± 2.54 versus 18.00 ± 2.87) [Figure 
2C(i)]. Consistent with clinical EAE, mice that received NAD 
108–120 showed dose-dependent perivascular infiltrations 
in the brains and spinal cords, and the inflammatory foci 
in animals that received 200 μg of NAD 108–120 were com-
parable to those immunized with MBP 89–101 [Table 1(i)]. 
Likewise, regardless of the immunogens used, inflamma-
tory changes were found in both meninges and parenchyma, 
with a tendency for lesions to be seen more in meninges than 
parenchyma as evaluated at different time points (day 16 or 
30) post-immunization, and the infiltrations were composed 
predominantly of lymphocytes, with few histiocytes and 
plasma cells [Figure 3A]. Verification of these results in naive 
mice did not reveal any of the changes described above (data 
not shown). We next verified encephalitogenic potential of 
NAD 108–120 in adoptive transfer experiments by injecting 
the lymphoblasts obtained from mice immunized with the 
corresponding peptides as described previously (24, 25). As 
shown in Figure 2B, LNC from mice immunized with MBP 
89–101 or NAD 108–120 induced the disease in all the naive 
SJL recipients (100%) with comparable mean days of onset 
(11.40 ± 0.51 versus 11.80 ± 0.73) and mean maximum scores 
(2.20 ± 0.20 versus 2.00 ± 0) [Table 1(ii)]. The disease severity, 
Figure 2. NAD 108–120 induces autoimmune encephalomyelitis 
similar to MBP 89–101. (A) EAE induction by active immunization. 
Groups of SJL mice were immunized with the indicated amounts 
of MBP 89–101 or NAD 108–120 in CFA twice with an interval of 
1 week and PT was administered on day 0 and 2 after the first im-
munization. The mice were monitored for clinical signs of EAE and 
scored. (B) EAE induction by adoptive transfer. Seven days after the 
second immunization with MBP 89–101 or NAD 108–120, the mice 
were killed and LNC were harvested from the draining LN. LNC 
were stimulated with Con-A for 2 days and viable lymphoblasts 
were injected into naive SJL mice intraperitoneally. Each mouse re-
ceived PT (400 ng) on day 0 and 2 post-transfer and the animals 
were observed for signs of EAE and scored. Mean values for a group 
of mice are shown. (C) Cumulative scores. Cumulative scores were 
obtained by adding the neurological scores for each mouse and 
compared between groups. Each bar represents mean ± SEM values 
for a group of mice.
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the core motif of the 10-amino acid fragment within MBP 85–
99 (VVHFFKNIVT) represents an epitope center for recogni-
tion by both MHC/TCR and auto-antibodies; for the latter, 
however, the FFK sequence has to be conserved (5). Similar to 
MBP 85–99, NAD 108–120 also possesses all the major MHC- 
and TCR-contact residues but the question is whether it can 
elicit cross-reactive T cells and trigger CNS autoimmunity in 
humans. To address this possibility, we derived a homology 
model for NAD 104–118/HLA-DR2 to determine whether 
the configuration and orientations of the critical MHC-and 
TCR-contact residues in cognate and mimicry epitopes fol-
low similar patterns. The homology model indicated that 
orientation of the side chains of the two critical MHC-anchor 
residues Ph92/111 and Asn94/113 and one major TCR-con-
tact residue, Phe91/110 in MBP 85–99/NAD 104–118 super-
posed comparably suggesting that the mimicry epitope can 
potentially anchor HLA-DR2 molecule similar to MBP 85–99 
and also to be recognized by MBP 85–99 specific TCR. We 
also propose that NAD 108–120 has the potential to activate 
MBP-specific B cells. We make this prediction because the 
stretch of three amino acids, FFK within the epitope center 
of MBP 85–99 (VVHFFKNIVT) is highly critical for MBP-
specific auto-antibody recognition (5). Ironically, microbial 
peptides bearing sequences identical to the epitope center 
of MBP 85–99 have been previously shown to bind MBP-
specific auto-antibodies derived from MS brain tissue and 
the binding correlated with the number of identical residues 
in the epitope center (5). These include one peptide from L2 
protein of human papillomavirus (VHFFK-I), which bound 
best to MBP-specific antibody followed by the peptides de-
rived from Bacillus subtilis (FFKNI) and Clostridium cellulare 
(FFKN). The fact that NAD 108–120 also possesses identical 
residues similar to the above (V-FFKNI) suggests that NAD 
108–120 can also bind to MBP-specific auto-antibodies.
In this study, using both active and AT-EAE protocols, we 
show that NAD 108–120 induces autoimmune encephalomy-
elitis in SJL mice by generating cross-reactive T cells for MBP 
89–101 and the T cells preferentially produce Th1 and Th17 
cytokines that favor CNS autoimmunity. The induction of 
cross-reactive T cell responses was expected because the core 
region of NAD 108–120 has a high degree of similarity with 
MBP 89–101. This region potentially contains critical MHC–
TCR-contact residues as shown in human MBP 85–99 (21), 
which might have led to the generation of cross-reactive T 
cells for MBP. However, the inflammatory foci in the CNS
(Figure 5A). Nonetheless, comparison of MBP-versus NAD-
stimulated cultures for frequencies of cells producing differ-
ent cytokines did not reveal any striking differences except 
that Th17 cytokine-secreting cells tended to be low in NAD 
108–120 cultures. Verification of these results by cytokine 
ELISA revealed no detectable amounts of IL-4, but Th1 and 
Th17 cytokines were detected with no skewing toward IL-
22 secretion (Figure 5C). Comparative analysis revealed 
that MBP 89–101 stimulated culture supernatants had more 
of both Th1 and Th17 cytokines, including GM-CSF, than 
those from NAD 108–120 sensitized cultures; the respective 
amounts were 701.36 ± 169.19 versus 72.50 ± 30.94; 451.51 ± 
77.99 versus 45.23 20.73 and 128.58 ± 48.59 versus 8.00 ± 2.25 
pg (P ≤ 0.001). Taken together, the data suggest that NAD 
108–120 can induce the generation of Th1 and Th17 cytokine-
secreting cells but to a lesser magnitude than MBP 89–101.
T cells sensitized with MBP 89–101 or NAD 108–120 use similar 
TCR vβs
To determine whether T cells sensitized with cognate and 
mimicry epitopes use similar TCR vβs, we analyzed their us-
age in CD4 T cells in cultures prepared from mice immu-
nized with the corresponding peptides by FC. We noted that 
expression of TCRvβs were found consistently in the order of 
vb4, vb2, vb17a, vβ6, vβ14, vβ3, vβ7, vβ5.1 and vβ5.2 in the 
cultures stimulated with either MBP 89–101 or NAD 108–120 
(Figure 6). While, the vβ usage was mostly constituted by 
vβ4, vβ2, vβ17a, vβ6 and vβ14, there were no significant dif-
ferences between the cultures stimulated with MBP 89–101 or 
NAD 108–120 (59.45 versus 57.56%), suggesting that cognate 
and mimicry epitopes sensitize similar T-cell repertoires.
Discussion
In this report, we present evidence that NAD 108–120 induc-
es autoimmune encephalomyelitis through the generation of 
cross-reactive T cells for MBP 89–101. MBP is one of the major 
candidate autoantigens identified in EAE/MS pathogenesis 
(2, 30). The mouse MBP sequence spanning amino acids 89–
101 has been shown to induce EAE in SJL mice (8, 31, 32), and 
the human MBP 85–99 sequence equivalent to mouse MBP 
89–101 matches 100%. Numerous studies indicate that T cells 
and B cells from MS patients show reactivity to MBP; in addi-
tion, MBP 85–99 has been recognized as one of the major im-
munodominant epitopes in MS patients bearing HLA-DR2 
haplotype (HLA-DRB*1501, DQB1*0602) (5, 33, 34). Indeed, 
Table 1. Clinical and histologic EAE in SJL mice induced with MBP 89–101 and NAD 108–120a
Treatment     Clinical disease                                  No. of inflammatory foci
          Incidence (%)    Mean day of onsetb    Mean maximum scoreb    Meninges     Parenchyma       Total
(i) EAE induction by active immunization
MBP 89–101
200 μg         9/11 (81.8)        12.10 ± 0.94         2 ± 0.15             4.18 ± 1.36      2.27 ± 0.75         6.45 ± 2.01
NAD 108–120
50 μg           2/4 (50)            0             0                   1 ± 0.71        0 ± 0            1 ± 0.71
100 μg           3/4 (75)          14 ± 0.00         1 ± 0.00               6.5 ± 4.57        0.75 ± 0.48         7.25 ± 4.99
200 μg        11/11 (100)         12 ± 1.32        1.09 ± 0.23             9.09 ± 3.80      3.73 ± 1.14        12.82 ± 4.53
(ii) EAE induction by adoptive transfer
MBP 89–101      5/5(100)         11.4 ± 0.51        2.2 ± 0.2              10.4 ± 6.65       11 ± 7.07         21.4 ± 13.69
NAD 108–120     5/5(100)         11.8 ± 0.73         2 ± 0                   6 ± 2.51        1.4 ± 0.93           7.4 ± 2.04
Scoring scale: 0, healthy; 1, decreased tail and body tone; 2, a clumsy but otherwise normal gait; 3, definite weakness of one or more limbs; 4, a 
paraplegic or monoplegic state; 5, a premorbid state.
aNumbers are mean ± SEM.
bRepresents only mice that showed clinical disease.
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evaluated using IAs/PLP 139–151 tetramers (20). Although 
cytokines induced with MBP 89–101 or NAD 108–120 follow 
the same pattern as above, the IL-22-secreting cells domi-
nated Th17 responses. While IL-17 and IL-22 participate in 
innate immune responses (35, 36), IL-22 can exert both pro-
and anti-inflammatory effects, but the role of IL-22 in organ-
specific autoimmune diseases is controversial. For example, 
IL-22 potentiates chronic inflammatory diseases such as 
arthritis, inflammatory bowel disease and psoriasis but not 
CNS inflammation in the mouse model of EAE (37–41). En-
dothelial cells in the blood-brain barrier, however, express 
receptors for IL-17 and IL-22, and both cytokines can pro-
mote CD4 T-cell recruitment in MS lesions (42). On the con-
trary, IL-22 mediates protection in T-cell-mediated hepatitis 
and autoimmune myocarditis (40, 43, 44). The finding that 
IL-22 is a T-cell-derived cytokine, the receptors for which are 
abundantly expressed in the non-lymphoid tissues, suggests 
that IL-22 can modulate inflammatory responses in the local 
milieu (36). Alternatively, multiple cytokines might coopera-
tively regulate CNS inflammation.
lesions induced by these cells tended to be low [Table 1(ii)], 
which may be due to the presence of a low proportion of Th17 
cytokine-secreting cells (Figure 5). Both Th1 and Th17 cells are 
critical to the mediation of CNS autoimmunity (27, 28), but 
the proportion of cytokines produced by each subset appears 
to be antigen dependent. For example, in our hands, we not-
ed that antigen-specific cells from SJL mice immunized with 
PLP 139–151 secrete a higher proportion of both IFN-γ and 
IL-17, with a tendency for IFN-γ to be higher than IL-17, as
Figure 3. Histological evaluation of CNS inflammation induced 
with MBP 89–101 or NAD 108–120. (A) EAE induction by active 
immunization. Brains and spinal cords harvested on day 16 and 
day 30 from mice immunized with MBP 89–101 or NAD 108–120 
show perivascular lymphocytic infiltrations (arrows) as evaluated 
by hematoxylin and eosin staining. (B) EAE induction by adoptive 
transfer. Hematoxylin and eosin sections show mixed perivascular 
cuffing (arrows) in the brains and spinal cords of mice that received 
lymphocytes generated from mice immunized with MBP 89–101 or 
NAD 108–120. Original magnification, 3400 (bar = 20 μm).
Figure 4. MBP 89–101 and NAD 108–120 induce cross-reactive T-cell 
responses. (A) First-round stimulation. Groups of mice were immu-
nized with MBP 89–101 or NAD 108–120 and 10 days later, animals 
were killed and the draining LN were collected. LNC were stimulat-
ed with the indicated peptides for 2 days followed by pulsing with 
3[H]thymidine, the incorporation of which was measured as c.p.m. 
16 h later. TMEV 70–86, control. Mean ± SEM values for a group 
of mice are shown each involving up to five mice per group (MBP 
89–101, n =7; NAD 108–120, n = 4). (B) Second-round stimulation. 
LNC obtained from MBP 89–101 or NAD 108–120 immunized mice 
were stimulated with the respective peptides twice with an interval 
of approximately 10–14 days as described in the Methods and the 
proliferative responses were measured as above. Mean ± SEM val-
ues for a group of mice each involving two to three mice are shown 
(MBP 89–101, n =3; NAD 108–120, n =4).
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ity that cognate and mimicry epitopes sensitize distinct T-cell 
clones (20). One possibility could be that skewed expansion 
of T-cell clones expressing particular TCR vbs influences the 
disease outcome, depending on the clones’ disease-inducing 
abilities. Alternatively, exposure to mimicry epitopes might 
lead to the expansion of hidden clones not usually respon-
sive to cognate peptides. To address these possibilities, we 
evaluated TCR vβ usage of CD4 cells sensitized with MBP 
89–101 or NAD 108–120, but we did not observe any striking 
differences between the two. Nonetheless, T cells expressing 
TCR vβ4, vβ2, vβ17a, vβ6, vβ14 and vβ3 were dominant in 
the cultures stimulated with either peptide, and these pro-
files were similar to those observed in PLP 139–151-sen-
sitized cells (20, 45, 46). The data suggest that autoreactive 
T-cell responses generated in a given mouse strain tend to 
follow a similar pattern of TCR vβ usage regardless of the 
immunogens used.
MS is a complex disease and no known etiological agents 
have been identified. Two major factors have been impli-
cated in the initiation of the disease: genetic susceptibility 
and exposure to environmental factors (2). In support of the 
latter, exacerbations of MS attacks or temporal alterations in 
the disease course have been linked to exposure primarily 
to virus infections such as EBV and HHV-6, but the clini-
cal evidence remains elusive (12–14). The current dogma is 
that MS does not appear to follow Koch’s postulates in that 
We recently reported that the TCR vβ usage of cross-reac-
tive cells for PLP 139–151 induced with ACA 83–95 differs 
from those induced with PLP 139–151, suggesting a possibil-
Figure 5. MBP 89–101 and NAD 108–120 induce similar cytokine profiles. (A) Intracellular cytokine staining. LNC obtained from mice immu-
nized with MBP 89–101 and NAD 108–120 were stimulated with the corresponding peptides for 2 days and the cultures were maintained in 
IL-2 medium for additional 2 days. Viable lymphoblasts were harvested and stimulated for ;4.5 h with PMA and Ionomycin in the presence of 
GolgiStop and the cells were stained with anti-CD4 and 7-AAD. After fixation and permeabilization, the cells were incubated with cytokine an-
tibodies and the frequencies of cytokine-secreting cells were determined by FC in the live (7-AAD) CD4 subset. (B) Comparison between Th1, Th 
2 and Th17 cytokine-secreting cells. Frequencies of CD4 cells producing IFN-γ, IL-4 and IL-10 and IL-17A, IL-17F and IL-22 corresponding to the 
indicated Th subsets were added together and compared between groups. (C) Cytokine ELISA. Supernatants harvested on day 2 poststimulation 
prior to the addition of IL-2 medium from the above cultures were analyzed for cytokines by ELISA. Each bar in the above represents mean ± 
SEM values for a group of mice.
Figure 6. MBP 89–101 and NAD 108–120 sensitized T cells show sim-
ilar TCR vβ usage. Ten days after immunization with MBP 89–101 
or NAD 108–120, the mice were killed and the draining LN were 
collected. LNC were stimulated with the corresponding peptides 
for 2 days and maintained in IL-2 medium. Cells were harvested on 
day 4 post-stimulation and stained with a panel of anti-TCR vβ and 
anti-CD4 and 7-AAD. After acquiring the cells by FC, percentages of 
TCR vβ+CD4+ cells were determined in the live (7-AAD) population. 
Each bar represents mean ± SEM values obtained from three to four 
experiments each involving one to two mice per group.
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a result of antigenic mimicry in genetically susceptible indi-
viduals who potentially carry pathogenic autoreactive T-cell 
and B-cell repertoires.
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